These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35337933)

  • 21. Limitations of presently available glycopeptides in the treatment of Gram-positive infection.
    Ziglam HM; Finch RG
    Clin Microbiol Infect; 2001; 7 Suppl 4():53-65. PubMed ID: 11688535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of resistant gram-positive infection: value of glycopeptide antibiotics vancomycin and teicoplanin].
    Waldvogel F
    Schweiz Med Wochenschr; 1993 Dec; 123(50):2353-6. PubMed ID: 8272810
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative in vitro activities of daptomycin, vancomycin, teicoplanin and linezolid against resistant Gram-positive bacterial isolates from two large centres in western India.
    Biswas S; Watwani J; Vadwai V; Shetty A; Kelkar R; Rodrigues C
    Int J Antimicrob Agents; 2012 Dec; 40(6):567-9. PubMed ID: 22947124
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic.
    Candiani G; Abbondi M; Borgonovi M; Romanò G; Parenti F
    J Antimicrob Chemother; 1999 Aug; 44(2):179-92. PubMed ID: 10473224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
    Grüneberg RN; Hryniewicz W
    Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daptomycin.
    Tedesco KL; Rybak MJ
    Pharmacotherapy; 2004 Jan; 24(1):41-57. PubMed ID: 14740787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daptomycin.
    Heidary M; Khosravi AD; Khoshnood S; Nasiri MJ; Soleimani S; Goudarzi M
    J Antimicrob Chemother; 2018 Jan; 73(1):1-11. PubMed ID: 29059358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A current perspective on daptomycin for the clinical microbiologist.
    Humphries RM; Pollett S; Sakoulas G
    Clin Microbiol Rev; 2013 Oct; 26(4):759-80. PubMed ID: 24092854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are glycopeptides still appropriate and convenient for empiric use?
    Gonzalez-Ruiz A; Richardson J
    J Chemother; 2008 Oct; 20(5):531-41. PubMed ID: 19028614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008).
    Bell JM; Turnidge JD; Sader HS; Jones RN
    Pathology; 2010; 42(5):470-3. PubMed ID: 20632825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-gram-positive agents. What we have and what we would like.
    Grüneberg RN
    Drugs; 1997; 54 Suppl 6():29-38. PubMed ID: 9474479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro activity of daptomycin and other antimicrobial agents against 499 strains of gram-positive cocci causing bloodstream infection].
    Yang QW; Wang H; Sun HL; Xu YC; Xie XL; Chen MJ
    Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):220-4. PubMed ID: 19576091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.